当前位置:首页 - 行情中心 - 东方生物(688298) - 财务分析 - 现金流量表

东方生物

(688298)

  

流通市值:54.79亿  总市值:54.79亿
流通股本:2.02亿   总股本:2.02亿

现金流量表

报告期2024-06-302024-03-312023-12-312023-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金374,399,530.64169,925,066.94574,190,596.17397,965,063.53
收到的税费返还24,594,757.6414,949,483.1238,233,277.7150,740,089.42
收到其他与经营活动有关的现金78,743,873.7343,844,393.07265,171,664.16179,563,331.77
经营活动现金流入的平衡项目0000
经营活动现金流入小计477,738,162.01228,718,943.111,077,595,538.03728,268,484.72
购买商品、接受劳务支付的现金318,730,944.98190,845,757.931,486,672,469.041,373,748,907.99
支付给职工以及为职工支付的现金264,430,384.98144,283,947614,600,364.4510,205,541.28
支付的各项税费28,678,025.0920,847,373.53213,919,821.07207,446,959.37
支付其他与经营活动有关的现金198,266,000.2484,606,841.56407,993,414.14256,542,179.32
经营活动现金流出的平衡项目0000
经营活动现金流出小计810,105,355.29440,583,920.022,723,186,068.652,347,943,587.96
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额-332,367,193.28-211,864,976.91-1,645,590,530.62-1,619,675,103.24
二、投资活动产生的现金流量:
收回投资收到的现金317,974,785532,446,296.68552,582,438.27468,760,000
取得投资收益收到的现金26,250,840.186,616,831.1843,512,776.7454,876,310.81
处置固定资产、无形资产和其他长期资产收回的现金净额21,20020,800814,437.5428,600
收到的其他与投资活动有关的现金1,271,121,065.87-63,400,00014,200,000
投资活动现金流入的平衡项目0000
投资活动现金流入小计1,615,367,891.05539,083,927.86660,309,652.55537,864,910.81
购建固定资产、无形资产和其他长期资产支付的现金383,798,704.01243,924,189.55996,047,135.96538,793,956.31
投资支付的现金123,000,000352,067,659.4471,047,200.92157,678,652.76
取得子公司及其他营业单位支付的现金322,414,10243,823,991.6378,523,355.4960,523,355.49
支付其他与投资活动有关的现金1,646,730,300-1,232,446,680.462,680,000
投资活动现金流出的平衡项目0000
投资活动现金流出小计2,475,943,106.01639,815,840.582,778,064,372.83759,675,964.56
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-860,575,214.96-100,731,912.72-2,117,754,720.28-221,811,053.75
三、筹资活动产生的现金流量:
吸收投资收到的现金360,000360,000-0
取得借款收到的现金184,700,000105,600,000772,000,000701,000,000
收到其他与筹资活动有关的现金---0
筹资活动现金流入平衡项目0000
筹资活动现金流入小计185,060,000105,960,000772,000,000701,000,000
偿还债务支付的现金197,000,000126,000,000318,500,000268,887,812.5
分配股利、利润或偿付利息支付的现金7,427,787.284,041,127.72373,405,258.33390,641,397.99
其中:子公司支付给少数股东的股利、利润--22,265,570.51-
支付其他与筹资活动有关的现金289,064,521.025,945,376.4530,558,476.36,148,033.98
筹资活动现金流出平衡项目0000
筹资活动现金流出小计493,492,308.3135,986,504.17722,463,734.63665,677,244.47
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额-308,432,308.3-30,026,504.1749,536,265.3735,322,755.53
四、汇率变动对现金及现金等价物的影响33,614,092.029,312,629.0785,852,483.4294,542,948.62
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额-1,467,760,624.52-333,310,764.73-3,627,956,502.11-1,711,620,452.84
加:期初现金及现金等价物余额2,928,603,342.172,928,603,342.176,556,559,844.286,556,559,844.28
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额1,460,842,717.652,595,292,577.442,928,603,342.174,844,939,391.44
补充资料:
净利润-160,044,012.22--418,268,830.43-
资产减值准备9,024,879.15-236,508,701.39-
固定资产和投资性房地产折旧49,532,272.35-64,358,757.32-
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧49,532,272.35-64,358,757.32-
无形资产摊销38,563,767.55-86,966,999.34-
长期待摊费用摊销10,287,177.92-18,003,899.36-
处置固定资产、无形资产和其他长期资产的损失55,152.15-178,965.39-
固定资产报废损失8,794.02-462,796-
公允价值变动损失-15,460,200.59-8,989,798.01-
财务费用-230,558.16--69,048,443.13-
投资损失-42,503,594.04--42,014,305.37-
递延所得税-9,053,441.09--27,750,951.13-
其中:递延所得税资产减少-9,083,476.88--25,022,165.55-
递延所得税负债增加30,035.79--2,728,785.58-
存货的减少-108,277,188.44--86,227,960.58-
经营性应收项目的减少60,932,256.31-210,277,696.5-
经营性应付项目的增加-183,160,616.82--1,669,724,911.32-
现金的期末余额1,460,842,717.65-2,928,603,342.17-
减:现金的期初余额2,928,603,342.17-6,556,559,844.28-
公告日期2024-08-302024-04-302024-04-302023-10-31
审计意见(境内)标准无保留意见
TOP↑